

Ichizo Tsujino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2489049/publications.pdf>

Version: 2024-02-01

66
papers

2,170
citations

304743

22
h-index

223800

46
g-index

67
all docs

67
docs citations

67
times ranked

2511
citing authors

#	ARTICLE	IF	CITATIONS
1	Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. <i>European Heart Journal</i> , 2005, 26, 1538-1543.	2.2	360
2	Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 933-941.	6.4	301
3	The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial 18F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. <i>Journal of Nuclear Cardiology</i> , 2016, 23, 244-252.	2.1	142
4	Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). <i>Circulation Journal</i> , 2019, 83, 842-945.	1.6	132
5	Associations among the plasma amino acid profile, obesity, and glucose metabolism in Japanese adults with normal glucose tolerance. <i>Nutrition and Metabolism</i> , 2016, 13, 5.	3.0	131
6	Validation Study on the Accuracy of Echocardiographic Measurements of Right Ventricular Systolic Function in Pulmonary Hypertension. <i>Journal of the American Society of Echocardiography</i> , 2012, 25, 280-286.	2.8	125
7	18F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1773-1783.	6.4	124
8	Comparison of 18F-fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance (CMR) in corticosteroid-naïve patients with conduction system disease due to cardiac sarcoidosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 259-269.	6.4	73
9	Elevated 18F-fluorodeoxyglucose uptake in the interventricular septum is associated with atrioventricular block in patients with suspected cardiac involvement sarcoidosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1558-1566.	6.4	50
10	Right atrial volume and phasic function in pulmonary hypertension. <i>International Journal of Cardiology</i> , 2013, 168, 420-426.	1.7	45
11	Imaging of Cardiac Sarcoid Lesions Using Fasting Cardiac ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography: An Autopsy Case. <i>Circulation</i> , 2010, 122, 535-536.	1.6	44
12	Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: A systematic review. <i>Respiratory Investigation</i> , 2018, 56, 332-341.	1.8	42
13	Right atrial volume and reservoir function are novel independent predictors of clinical worsening in patients with pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 414-423.	0.6	41
14	Right ventricular 18F-FDG uptake is an important indicator for cardiac involvement in patients with suspected cardiac sarcoidosis. <i>Annals of Nuclear Medicine</i> , 2014, 28, 656-663.	2.2	40
15	Multi-institutional retrospective cohort study of patients with severe pulmonary hypertension associated with respiratory diseases. <i>Respirology</i> , 2015, 20, 805-812.	2.3	38
16	Cardiac sarcoidosis classification with deep convolutional neural network-based features using polar maps. <i>Computers in Biology and Medicine</i> , 2019, 104, 81-86.	7.0	36
17	Use of 18F-FDG PET/CT texture analysis to diagnose cardiac sarcoidosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1240-1247.	6.4	36
18	Simple prediction of right ventricular ejection fraction using tricuspid annular plane systolic excursion in pulmonary hypertension. <i>International Journal of Cardiovascular Imaging</i> , 2013, 29, 1799-1805.	1.5	31

#	ARTICLE	IF	CITATIONS
19	Paradoxical Interventricular Septal Motion as a Major Determinant of Late Gadolinium Enhancement in Ventricular Insertion Points in Pulmonary Hypertension. PLoS ONE, 2013, 8, e66724.	2.5	30
20	Incidence and Clinical Features of Venous Thromboembolism in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) in Japan. Circulation Journal, 2021, 85, 2208-2214.	1.6	30
21	Selexipag for the treatment of chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2022, 60, 2101694.	6.7	26
22	18F-FMISO PET/CT detects hypoxic lesions of cardiac and extra-cardiac involvement in patients with sarcoidosis. Journal of Nuclear Cardiology, 2021, 28, 2141-2148.	2.1	23
23	Early Detection of Cardiac Sarcoid Lesions with 18F-fluoro-2-deoxyglucose Positron Emission Tomography. Internal Medicine, 2011, 50, 1207-1209.	0.7	22
24	Combination of 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in assessing cardiac sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2005, 22, 234-5.	0.2	22
25	Broad and heterogeneous vasculopathy in pulmonary fibrosis and emphysema with pulmonary hypertension. Respirology Case Reports, 2013, 1, 10-13.	0.6	20
26	The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in Japan: From the CLOT-COVID study. Journal of Cardiology, 2022, 80, 285-291.	1.9	18
27	Which is the proper reference tissue for measuring the change in FDG PET metabolic volume of cardiac sarcoidosis before and after steroid therapy?. EJNMMI Research, 2018, 8, 94.	2.5	15
28	Performance of computed tomography-derived pulmonary vasculature metrics in the diagnosis and haemodynamic assessment of pulmonary arterial hypertension. European Journal of Radiology, 2017, 96, 31-38.	2.6	14
29	Influence of sex on development of thrombosis in patients with COVID-19: From the CLOT-COVID study. Thrombosis Research, 2022, 213, 173-178.	1.7	12
30	Multi-Institutional Prospective Cohort Study of Patients With Pulmonary Hypertension Associated With Respiratory Diseases. Circulation Journal, 2021, 85, 333-342.	1.6	10
31	The rate of myocardial perfusion recovery after steroid therapy and its implication for cardiac events in cardiac sarcoidosis and primarily preserved left ventricular ejection fraction. Journal of Nuclear Cardiology, 2021, 28, 1745-1756.	2.1	9
32	Prognostic value of phase analysis on gated single photon emission computed tomography in patients with cardiac sarcoidosis. Journal of Nuclear Cardiology, 2021, 28, 128-136.	2.1	9
33	Chinese herbal medicine Qing-Dai-induced pulmonary arterial hypertension in a patient with ulcerative colitis: A case report and experimental investigation. Respiratory Medicine Case Reports, 2019, 26, 265-269.	0.4	8
34	Accuracy of echocardiographic indices for serial monitoring of right ventricular systolic function in patients with precapillary pulmonary hypertension. PLoS ONE, 2017, 12, e0187806.	2.5	7
35	Underdiagnosis of cardiac sarcoidosis by ECG and echocardiography in cases of extracardiac sarcoidosis. ERJ Open Research, 2022, 8, 00516-2021.	2.6	7
36	Current trends in the management of pulmonary hypertension associated with respiratory disease in institutions approved by the Japanese Respiratory Society. Respiratory Investigation, 2014, 52, 167-172.	1.8	6

#	ARTICLE	IF	CITATIONS
37	The Effects of Pulmonary Vasodilating Agents on Right Ventricular Parameters in Severe Group 3 Pulmonary Hypertension: A Pilot Study. <i>Pulmonary Circulation</i> , 2016, 6, 524-531.	1.7	6
38	Successful treatment of tocilizumab-resistant large vessel pulmonary arteritis with infliximab. <i>Immunological Medicine</i> , 2018, 41, 39-42.	2.6	5
39	Reduced diffusing capacity for carbon monoxide predicts borderline pulmonary arterial pressure in patients with systemic sclerosis. <i>Rheumatology International</i> , 2019, 39, 1883-1887.	3.0	5
40	A histopathological report of a 16-year-old male with peripheral pulmonary artery stenosis and Moyamoya disease with a homozygous RNF213 mutation. <i>Respiratory Medicine Case Reports</i> , 2020, 29, 100977.	0.4	5
41	Right ventriculo-pulmonary arterial uncoupling and poor outcomes in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2020, 10, 1-11.	1.7	5
42	Psychometric Validation of a Japanese Version of the emPHasis-10 Questionnaire, a Patient-Reported Outcome Measure for Pulmonary Hypertension—Multicenter Study in Japan. <i>Circulation Reports</i> , 2020, 2, 255-259.	1.0	5
43	Clinical Application of ¹⁸ F-fluorodeoxyglucose PET and LGE CMR in Cardiac Sarcoidosis. <i>Annals of Nuclear Cardiology</i> , 2017, 3, 125-130.	0.2	5
44	Hemodynamic effects of ambrisentan-tadalafil combination therapy on progressive portopulmonary hypertension. <i>World Journal of Hepatology</i> , 2014, 6, 825.	2.0	5
45	A case of idiopathic constrictive bronchiolitis in a middle-aged male smoker. <i>Respirology</i> , 2000, 5, 305-307.	2.3	4
46	Four cases with group 3 out-of-proportion pulmonary hypertension with a favorable response to vasodilators. <i>Respiratory Medicine Case Reports</i> , 2013, 9, 4-7.	0.4	4
47	Amelioration of right ventricular systolic function and stiffness in a patient with idiopathic pulmonary arterial hypertension treated with oral triple combination therapy. <i>Pulmonary Circulation</i> , 2018, 8, 1-5.	1.7	4
48	Right ventricular function as assessed by cardiac magnetic resonance imaging-derived strain parameters compared to high-fidelity micromanometer catheter measurements. <i>Pulmonary Circulation</i> , 2021, 11, 1-10.	1.7	4
49	D-Dimer Values and Venous Thromboembolism in Patients With COVID-19 in Japan—From the CLOT-COVID Study. <i>Circulation Reports</i> , 2022, , .	1.0	4
50	Therapeutic-Dose vs. Prophylactic-Dose Anticoagulation Therapy for Critically Ill Patients With COVID-19 in a Practice-Based Observational Study. <i>Circulation Journal</i> , 2022, 86, 1137-1142.	1.6	4
51	Replacement myocardial fibrosis at the site of late gadolinium enhancement on magnetic resonance imaging in a patient with diffuse cutaneous systemic sclerosis: An autopsy report. <i>Journal of Cardiology Cases</i> , 2017, 16, 48-51.	0.5	3
52	Accuracy of Swan-Ganz catheterization-based assessment of right ventricular function: Validation study using high-fidelity micromanometry-derived values as reference. <i>Pulmonary Circulation</i> , 2022, 12, e12078.	1.7	3
53	Phorbol 12-myristate 13-acetate stimulation under hypoxia induces nuclear swelling with DNA outflow but not extracellular trap formation of neutrophils. <i>Experimental and Molecular Pathology</i> , 2022, 125, 104754.	2.1	3
54	Association Between the Development of Thrombosis and Worsening of Disease Severity in Patients With Moderate COVID-19 on Admission—From the CLOT-COVID Study. <i>Circulation Journal</i> , 2023, 87, 448-455.	1.6	3

#	ARTICLE	IF	CITATIONS
55	Representative Chest Auscultation Findings in Pulmonary Hypertension: Phonocardiograms and Sound Clips. <i>Annals of the American Thoracic Society</i> , 2017, 14, e1-e3.	3.2	2
56	Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage. <i>Internal Medicine</i> , 2018, 57, 1769-1772.	0.7	2
57	Right ventricular dimension index by cardiac magnetic resonance for prognostication in connective tissue diseases and pulmonary hypertension. <i>Rheumatology</i> , 2019, 59, 622-633.	1.9	2
58	Improvements in French risk stratification score were correlated with reductions in mean pulmonary artery pressure in pulmonary arterial hypertension: a subanalysis of the Japan Pulmonary Hypertension Registry (JAPHR). <i>BMC Pulmonary Medicine</i> , 2021, 21, 28.	2.0	2
59	Determinants of altered left ventricular suction in pre-capillary pulmonary hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 1399-1406.	1.2	2
60	Measurement of exhaled nitric oxide concentration using nasal continuous negative pressure. <i>Respirology</i> , 1999, 4, 155-159.	2.3	1
61	Right ventricular pressure–volume loop produced with simultaneous application of three-dimensional echocardiography and high-fidelity micromanometry in a patient with pulmonary arterial hypertension. <i>Echocardiography</i> , 2021, 38, 805-807.	0.9	1
62	Efficient detection of pulmonary arterial hypertension using serum haptoglobin level and cardiac MRI in patients with connective tissue diseases: a pilot study. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 345-346.	0.8	1
63	Enhanced computed tomography unveiling the underlying cause of pulmonary hypertension. <i>International Journal of Cardiovascular Imaging</i> , 2010, 26, 257-258.	1.5	0
64	Pulmonary capillary hemangiomas-predominant vasculopathy in a patient with rheumatoid arthritis-associated interstitial lung disease: An autopsy report. <i>Respiratory Medicine Case Reports</i> , 2020, 31, 101215.	0.4	0
65	The assessment of left heart disease in patients with systemic sclerosis and pulmonary hypertension. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 103-110.	0.8	0
66	The assessment of left heart disease in patients with systemic sclerosis and pulmonary hypertension. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 103-110.	0.8	0